157 related articles for article (PubMed ID: 34535038)
1. Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights.
Parlak C; Alver Ö; Ouma CNM; Rhyman L; Ramasami P
Drug Res (Stuttg); 2022 Jan; 72(1):34-40. PubMed ID: 34535038
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
Shahrbaf MA; Tabary M; Khaheshi I
Cardiovasc Hematol Disord Drug Targets; 2021; 21(2):88-90. PubMed ID: 34387172
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
Negru PA; Radu AF; Vesa CM; Behl T; Abdel-Daim MM; Nechifor AC; Endres L; Stoicescu M; Pasca B; Tit DM; Bungau SG
Biomed Pharmacother; 2022 Mar; 147():112700. PubMed ID: 35131656
[TBL] [Abstract][Full Text] [Related]
4. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
Sreekanth Reddy O; Lai WF
Chembiochem; 2021 Mar; 22(6):939-948. PubMed ID: 33031623
[TBL] [Abstract][Full Text] [Related]
5. Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human plasma.
Ramzy S; Abdelazim AH; Osman AO; Hasan MA
Spectrochim Acta A Mol Biomol Spectrosc; 2022 Nov; 281():121625. PubMed ID: 35863184
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV.
Kundu S; Sarkar D
Mini Rev Med Chem; 2022; 22(2):232-247. PubMed ID: 34254915
[TBL] [Abstract][Full Text] [Related]
7. Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far.
Saini M; Rana M; Bhatti K; Das R; Mehta DK; Chidurala RM
Curr Drug Res Rev; 2022; 14(1):11-19. PubMed ID: 34365935
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
9. Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir.
El-Awady M; Elmansi H; Belal F; Shabana RA
J Fluoresc; 2022 Sep; 32(5):1941-1948. PubMed ID: 35771341
[TBL] [Abstract][Full Text] [Related]
10. Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents.
Al-Ardhi FM; Novotny L; Alhunayan A; Al-Tannak NF
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Mar; 166(1):12-20. PubMed ID: 34782799
[TBL] [Abstract][Full Text] [Related]
11. Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Dong L; Hu S; Gao J
Drug Discov Ther; 2020; 14(1):58-60. PubMed ID: 32147628
[TBL] [Abstract][Full Text] [Related]
12. In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase.
Celik I; Erol M; Duzgun Z
Mol Divers; 2022 Feb; 26(1):279-292. PubMed ID: 33765239
[TBL] [Abstract][Full Text] [Related]
13. Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods.
Hoseininezhad-Namin MS; Rahimpour E; Jouyban A
Drug Metab Rev; 2024; 56(2):127-144. PubMed ID: 38445647
[TBL] [Abstract][Full Text] [Related]
14. Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models.
Wang Y; Li P; Rajpoot S; Saqib U; Yu P; Li Y; Li Y; Ma Z; Baig MS; Pan Q
Sci Rep; 2021 Dec; 11(1):23465. PubMed ID: 34873274
[TBL] [Abstract][Full Text] [Related]
15. Drug-Membrane Interactions: Effects of Virus-Specific RNA-Dependent RNA Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers.
Fischer M; Müller P; Scheidt HA; Luck M
Biochemistry; 2022 Jul; 61(13):1392-1403. PubMed ID: 35731976
[TBL] [Abstract][Full Text] [Related]
16. Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity.
Tsuji M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232311
[TBL] [Abstract][Full Text] [Related]
17. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
Choi SW; Shin JS; Park SJ; Jung E; Park YG; Lee J; Kim SJ; Park HJ; Lee JH; Park SM; Moon SH; Ban K; Go YY
Antiviral Res; 2020 Dec; 184():104955. PubMed ID: 33091434
[TBL] [Abstract][Full Text] [Related]
18. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Choy KT; Wong AY; Kaewpreedee P; Sia SF; Chen D; Hui KPY; Chu DKW; Chan MCW; Cheung PP; Huang X; Peiris M; Yen HL
Antiviral Res; 2020 Jun; 178():104786. PubMed ID: 32251767
[TBL] [Abstract][Full Text] [Related]
19. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
[TBL] [Abstract][Full Text] [Related]
20. Antiviral treatment of COVID-19.
Şimşek Yavuz S; Ünal S
Turk J Med Sci; 2020 Apr; 50(SI-1):611-619. PubMed ID: 32293834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
